SIREN : 381878040
PHARMALAND is a French company founded 35 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in PARIS (75001), this company of category ETI shows in 2021 a revenue of 14 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | 14 492 € | N/C | 708 € | 1 928 € | 6 431 € | 1 983 845 € |
| Net income | 398 834 € | 539 612 € | 2 504 748 € | 100 € | -20 444 € | -24 879 € | -21 763 € | 143 715 € | 65 671 € |
| EBITDA | -8 671 € | -7 275 € | -21 770 € | 6 389 € | -13 286 € | -17 616 € | -16 512 € | -21 384 € | 107 732 € |
| Net margin | N/C | N/C | N/C | 0.7% | N/C | -3514.0% | -1128.8% | 2234.7% | 3.3% |
In 2024, PHARMALAND generates positive net income of 399 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 66 k€ -> 399 k€.
-5 €
-8 671 €
-8 666 €
398 834 €
The debt ratio (= Financial debt / Equity x 100) stands at 535%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 15%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 8.3 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.
535.06%
15.193%
8.347
In 2024, the debt ratio of PHARMALAND (535.06) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of PHARMALAND (15.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of PHARMALAND (8.35) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 1.71. The company can meet its short-term commitments with a reasonable safety margin.
1.705
-1645.254
In 2024, the liquidity ratio of PHARMALAND (1.71) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of PHARMALAND (-1645.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 4977 days. Excellent situation: suppliers finance 4977 days of the operating cycle (retail model).
0 €
0 j
4977 j
0 j
Indicative estimate only : the number of comparable transactions in this sector is limited (26 transactions). This range of 1 120 194€ to 7 728 841€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 26 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMALAND with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of PHARMALAND in 2021 is 14 k€.
Yes, PHARMALAND generated a net profit of 399 k€ in 2024.
The headquarters of PHARMALAND is located in PARIS (75001), in the department Paris.
The tax return of PHARMALAND is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMALAND operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.